Clinical Trial Update: Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD [Phase 1]

View source ↗

Summary

Open-label Phase 1 pharmacokinetic study evaluating iron isomaltoside 1000 (Monofer) given as a 500 mg IV bolus or 1000 mg IV infusion in non-dialysis-dependent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Monofer (Ferric derisomaltose)

Snippet

Sponsor: Pharmacosmos A/S | Conditions: Non-dialysis Dependent Chronic Kidney Disease | Phase 1 | Status: COMPLETED